Financial Performance - The company's operating revenue for 2024 reached ¥511,619,303.14, a year-on-year increase of 70.61% compared to ¥299,871,288.42 in 2023[23]. - Net profit attributable to shareholders was ¥127,700,550.17, reflecting a significant growth of 109.09% from ¥61,074,068.07 in the previous year[23][25]. - The net profit after deducting non-recurring gains and losses was ¥113,965,967.97, up 140.06% from ¥47,473,745.81 in 2023[23][25]. - Cash flow from operating activities surged to ¥130,230,119.87, a remarkable increase of 905.01% compared to ¥12,958,036.70 in the previous year[23][27]. - Basic earnings per share rose to ¥0.28, marking a 115.38% increase from ¥0.13 in 2023[24][27]. - The weighted average return on equity increased to 10.37%, up 5.23 percentage points from 5.14% in the previous year[24][27]. - The total cash dividend for the year amounts to 27.84 million CNY, which includes 11.23 million CNY distributed in the mid-year[6]. - The combined amount of cash dividends and share repurchases for the year is approximately 63.96 million CNY, representing 50.09% of the net profit attributable to shareholders[6]. Research and Development - Research and development expenses accounted for 16.60% of operating revenue, a decrease of 8.08 percentage points from 24.68% in 2023[24][27]. - The total R&D expenditure for the year was approximately ¥84.92 million, an increase of 14.75% compared to the previous year's ¥74.01 million, with R&D expenditure accounting for 16.60% of operating revenue, down from 24.68%[79]. - The company has 19 products under development, with 5 products approved for domestic and international markets during the reporting period[36]. - A total of 16 new domestic patents were applied for during the reporting period, including 10 invention patents[37]. - The company has established three core technology platforms, enhancing its R&D capability and creating high barriers to entry in the market[87]. - The company has maintained a strong focus on independent R&D since its establishment, ensuring a solid foundation for the continuous development of high-value products[68]. - The company has a strong R&D team, with over 40% of its researchers holding master's degrees or higher, ensuring robust technical capabilities[90]. Market Expansion and Sales - The company is actively expanding its international market presence, focusing on the U.S. and emerging markets along the "Belt and Road" initiative[35]. - The company achieved foreign sales revenue of 20,794.62 million yuan, accounting for 40.69% of its main business income, indicating its reliance on international markets[95]. - The company recorded equity income of CNY 46.82 million, which is a 122.30% increase compared to the previous year[35]. - The company’s international sales revenue surged by 120.64% year-on-year, mainly due to substantial sales growth of Mesalazine enteric-coated tablets and Bupropion sustained-release tablets in the U.S.[117]. - The company’s main products, including posaconazole enteric-coated tablets and mesalazine enteric-coated tablets, have significant market shares in the U.S. market and are included in the National Basic Medical Insurance Drug List[89]. Quality Management and Compliance - The company has established a comprehensive quality management system, conducting 1 internal audit and passing 12 external inspections during the reporting period, ensuring stable production operations[39]. - The company received a zero-defect rating from the FDA during a routine cGMP inspection in March 2024, affirming the effectiveness of its quality management system[40]. - The company has established long-term partnerships with major suppliers to ensure stable and reliable material supply, employing various procurement models to maintain quality and cost-effectiveness[45]. - The company has received multiple awards for its CRO/CMO services, including recognition as one of the "Top Ten Innovative Drug Service Institutions" by Securities Times[38]. Risks and Challenges - The company faces risks related to raw material price fluctuations, which could impact future performance if prices rise significantly[96]. - The company has a receivables balance of 10,352.46 million yuan, indicating potential risks associated with accounts receivable as business expands[99]. - The company’s inventory value stands at 10,241.85 million yuan, posing risks related to the timely realization of inventory as business grows[100]. - The company faced risks related to the national centralized procurement policy, which may affect the pricing and sales of its products, particularly posaconazole enteric-coated tablets[106]. - The company’s foreign sales are significantly impacted by international regulations and geopolitical factors, which pose potential risks to its export business[108]. Corporate Governance - The company has established a robust governance structure, holding 8 board meetings and reviewing 35 proposals during the reporting period[174]. - The board of directors consists of 8 members, all of whom are external directors, including 3 independent directors, complying with legal and regulatory requirements[175]. - The supervisory board held 5 meetings during the reporting period, reviewing 16 proposals, ensuring compliance with relevant laws and regulations[176]. - The company has maintained independence from its controlling shareholder, with no instances of fund occupation or guarantees provided to the controlling shareholder[178]. - The company issued 5 voluntary disclosure announcements throughout the year, including 3 product approval announcements and 1 project bidding announcement, enhancing market transparency[179]. Future Outlook - The company plans to deepen its focus on high-end generic drugs and expand into improved new drugs, enhancing its competitive edge[168]. - The company aims to increase R&D investment, particularly in complex injection formulations, to transition from a generic drug company to a hybrid innovative pharmaceutical enterprise[169]. - The company will enhance its CRO/CMO services, expanding its client base and deepening cooperation with existing clients[170]. - The company intends to expand its market presence both domestically and internationally, particularly in emerging markets and along the "Belt and Road" initiative[171].

上海宣泰医药科技股份有限公司 内部控制审计报告 上会师报字(2025)第 8050 号 上会会计师事务所（特殊普通合伙） 中国 ·计师 李 务所（转张善通合伙） Certified Public Accountants (Special General Partnership) 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情 况的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根 据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 内部控制审计报告 上会师报字(2025)第 8050 号 上海宣泰医药科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们 审计了上海宣泰医药科技股份有限公司(以下简称"宣泰医药")2024年12月 31 日 的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评 价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是宣泰医药董事 会的责任。 二、注册会计师的责任 我们的责任是在实施审 ...

上会会计师事务所（特殊普通合伙） 中国 上海 the state of the state 令计师 李务所（特殊善通合伙） ahai Ecolidiad Public Slocoventants (Shocial Peneral Partnership) 关于上海宣泰医药科技股份有限公司 募集资金存放与使用情况的鉴证报告 上会师报字(2025)第 8051 号 关于上海宣泰医药科技股份有限公司 2024 年度募集资金存放与使用情况的鉴证报告 上会师报字(2025)第 8051 号 上海宣泰医药科技股份有限公司全体股东： 我们接受委托,对后附的上海宣泰医药科技股份有限公司(以下简称"宣泰医药") 《关于 2024 年度公司募集资金存放与实际使用情况的专项报告》执行了鉴证工作。 一、管理层对募集资金专项报告的责任 按照中国证监会发布的《上市公司监管指引第 2 号一上市公司募集资金管理和 使用的监管要求》和上海证券交易所发布的《上海证券交易所科创板上市公司自律 监管指引第 1 号 -- 规范运作》的规定编制《关于 2024年度公司募集资金存放与实 际使用情况的专项报告》是宣泰医药董事会的责任。这种责任包括设计、实施 ...

上会师报字(2025)第 8048 号 上海宣泰医药科技股份有限公司全体股东: 上海宣泰医药科技股份有限公司 审计报告 上会师报字(2025)第 8048 号 上会会计师事务所（特殊普通合伙） 中国 上海 ·计师事务所(特殊善通 lio Secountants (Sha 审计报告 一、审计意见 我们审计了上海宣泰医药科技股份有限公司（以下简称"宣泰医药"）财务报 表,包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司 利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及相关财务 报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公 允反映了宣泰医药 2024 年 12 月 31 目的合并及母公司财务状况以及 2024年度的合并 及母公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则,我们独立于宣泰医药,并履行了职业道德方面的其 他责任。我们相信,我们获取的审计证 ...

国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为上海 宣泰医药科技股份有限公司（以下简称"公司"或"宣泰医药"）的持续督导机 构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求》《上海证券交易所科创板股票上市规定》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规 定，对宣泰医药 2024 年度募集资金存放与使用情况进行了审慎核查，具体情况 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 国泰海通证券股份有限公司 关于上海宣泰医药科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公开发 行人民币普通股（A）股 45,340,000.00 股，发行价格为 9.37 元/股，募集资金总 额为人民币 42,483.58 万元，扣除与发行相关的费用（不含增值税）人民币 4,761.77 万元，实际募集资金净额为人民币 37,721. ...

金可使用手机 "扫一扫"直进入"结果没什得行业说"出管学会"(kqs/24cc)的公式拿手参见出身 【在行业】【 关于上海宣泰医药科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：上海宣泰医药科技股份有限公司 审计单位：上会会计师事务所（特殊普通合伙） 关于上海宣泰医药科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审核报告 上会师报字(2025)第 8049 号 上会会计师事务所(特殊普通合伙) 中国 上海 六 · anghai Certified Publio Secountants (Special General Partnership) 上海宜泰医药科技股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况汇总表的 专项审核报告 上会师报字(2025)第 8049 号 上海宜泰医药科技股份有限公司全体股东: 我们接受委托,依据《中国注册会计师执业准则》审计了上海宣泰医药科技股 份有限公司(以下简称"宣泰医药")2024年度的财务报表,包括 2024年 12 月 31 日的合并及母公司资产 ...

Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. reported significant growth in its 2024 annual results, with a revenue of 512 million yuan and a net profit of 128 million yuan, driven by strong sales and international market expansion [1][2]. Group 1: Financial Performance - In 2024, the company achieved an operating income of 512 million yuan, representing a year-on-year increase of 70.61% [1] - The net profit attributable to shareholders reached 128 million yuan, up 109.09% year-on-year, while the net profit after deducting non-recurring gains and losses was 114 million yuan, marking a 140.06% increase [1] - The company plans to distribute a cash dividend of 0.37 yuan per share, with a total dividend amounting to approximately 16.61 million yuan, which is over 50% of the net profit attributable to shareholders [1] Group 2: Sales Growth and Market Expansion - Product sales revenue for the year was 351 million yuan, a substantial increase of 99.64%, with revenue from equity participation reaching 46.82 million yuan, up 122.30% [2] - Key products such as Posaconazole enteric-coated tablets and Ursodeoxycholic acid capsules saw significant sales growth in the Chinese market, while Mesalazine enteric-coated tablets gained market share in the U.S. [2] - The company successfully commercialized several new products in China, including Sitagliptin Metformin extended-release tablets and Olaparib tablets, and expanded its international presence by signing multiple cooperation agreements in emerging markets [2] Group 3: Future Development Plans - In 2025, the company anticipates the completion of system certification for its complex formulation workshop, with the first complex injection project entering trial operations [3] - The company aims to enhance its R&D efforts in the injection field and develop new formulation platform technologies, transitioning from a generic drug company to a hybrid innovative pharmaceutical enterprise [3]

Core Insights - The company reported a significant increase in revenue and profit for the year 2024, with total revenue reaching 512 million yuan, a year-on-year growth of 70.61%, and a net profit attributable to shareholders of 128 million yuan, up 109.09% [1] - The company plans to distribute a cash dividend of 0.37 yuan per share, totaling approximately 16.61 million yuan, which represents over 50% of the net profit attributable to shareholders [1] Revenue Growth - The company achieved product sales revenue of 351 million yuan, marking a 99.64% increase year-on-year, with revenue from equity participation reaching 46.82 million yuan, up 122.30% [2] - Key products such as Posaconazole enteric-coated tablets and Ursodeoxycholic acid capsules saw substantial sales growth in the Chinese market, while Mesalazine enteric-coated tablets continued to gain market share in the U.S. [2] International Expansion - The company is actively expanding its international presence, focusing on the U.S. market while also exploring emerging markets and countries along the "Belt and Road" initiative [2] - As of the end of 2024, the company has received approval for 16 products, with sales extending to multiple countries including the U.S., Australia, Singapore, and Canada [2] CRO/CMO Business Development - The CRO/CMO business generated revenue of 84.91 million yuan, reflecting a year-on-year growth of 22.66% [3] - The company added seven new domestic and international innovative drug clients and facilitated the submission of IND applications for seven new compounds [3] R&D Investment and Innovation - The company invested 84.92 million yuan in R&D, a 14.75% increase from the previous year, and applied for 16 new domestic patents [5] - The company has received approval for five products domestically and internationally, including high-activity formulations [6] Market Trends and Strategic Focus - The global generic drug market is projected to grow from 426 billion USD in 2023 to over 600 billion USD by 2030, with high-tech barrier generics expected to dominate [4] - The company is committed to enhancing its core competitiveness through R&D, focusing on high-barrier products and complex injection technology platforms [4]

证券代码：688247 证券简称：宣泰医药 公告编号：2025-012 上海宣泰医药科技股份有限公司 关于持股 5%以上股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2025 年 3 月 21 日接到公司股东栖和创业通知，获悉其所持有公司的 部分股份办理了解除质押登记手续，具体事项如下： 一、本次股份解除质押情况 上海宣泰医药科技股份有限公司董事会 2025 年 3 月 25 日 | 持股比例 | 5.69% | | --- | --- | | 剩余被质押股份数量 | 12,000,000 | | 剩余被质押股份占其所持股份比例 | 46.52% | | 剩余被质押股份占公司总股本比例 | 2.65% | 上述质押事项如若出现其他重大变动情况，公司将按照有关规定及时履行信 息披露义务。 特此公告。 单位：股 | 股东名称 | 栖和创业 | | --- | --- | | 本次解除质押股份 | 13,750,000 | | 占其所持股份比例 | 53.30% | | 占公 ...

股东减持计划完成暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海宣泰医药科技股份有限公司（以下简称"宣泰医 药"或"公司"）股东南京市栖和创业投资合伙企业（有限合伙）（以下简称"栖 和创业"）持有公司股份 36,798,000 股，占公司总股本的 8.1171%。上述股份来 源为公司首次公开发行前取得的股份，已于 2023 年 8 月 25 日解除限售并上市流 通。 减持计划的实施结果情况 证券代码：688247 证券简称：宣泰医药 公告编号：2025-011 上海宣泰医药科技股份有限公司关于持股 5%以上 （一）大股东因以下事项披露减持计划实施结果： 减持计划实施完毕 | 股东名称 | 减持数量 | 减持比 | 减持期间 | 减持方式 | 减持价格区间 | 减持总金额 | 减持完 | 当前持有数 | 当前持 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...